• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

调节性T细胞中的PTEN信号通路是抑制性肿瘤微环境的关键驱动因素。

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.

作者信息

Sharma Madhav D, Shinde Rahul, McGaha Tracy L, Huang Lei, Holmgaard Rikke B, Wolchok Jedd D, Mautino Mario R, Celis Esteban, Sharpe Arlene H, Francisco Loise M, Powell Jonathan D, Yagita Hideo, Mellor Andrew L, Blazar Bruce R, Munn David H

机构信息

Cancer Center, Georgia Regents University, Augusta, GA 30912, USA. ; Department of Pediatrics, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA.

Cancer Center, Georgia Regents University, Augusta, GA 30912, USA.

出版信息

Sci Adv. 2015 Nov 6;1(10):e1500845. doi: 10.1126/sciadv.1500845. eCollection 2015 Nov.

DOI:10.1126/sciadv.1500845
PMID:26601142
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC4640592/
Abstract

The tumor microenvironment is profoundly immunosuppressive. We show that multiple tumor types create intratumoral immune suppression driven by a specialized form of regulatory T cell (Treg) activation dependent on the PTEN (phosphatase and tensin homolog) lipid phosphatase. PTEN acted to stabilize Tregs in tumors, preventing them from reprogramming into inflammatory effector cells. In mice with a Treg-specific deletion of PTEN, tumors grew slowly, were inflamed, and could not create an immunosuppressive tumor microenvironment. In normal mice, exposure to apoptotic tumor cells rapidly elicited PTEN-expressing Tregs, and PTEN-deficient mice were unable to maintain tolerance to apoptotic cells. In wild-type mice with large established tumors, pharmacologic inhibition of PTEN after chemotherapy or immunotherapy profoundly reconfigured the tumor microenvironment, changing it from a suppressive to an inflammatory milieu, and tumors underwent rapid regression. Thus, the immunosuppressive milieu in tumors must be actively maintained, and tumors become susceptible to immune attack if the PTEN pathway in Tregs is disrupted.

摘要

肿瘤微环境具有很强的免疫抑制作用。我们发现多种肿瘤类型会产生肿瘤内免疫抑制,这种抑制由一种特殊形式的调节性T细胞(Treg)激活所驱动,而该激活依赖于PTEN(磷酸酶和张力蛋白同源物)脂质磷酸酶。PTEN在肿瘤中起到稳定Treg的作用,阻止它们重编程为炎性效应细胞。在PTEN特异性缺失的Treg小鼠中,肿瘤生长缓慢、出现炎症,且无法形成免疫抑制性肿瘤微环境。在正常小鼠中,暴露于凋亡肿瘤细胞会迅速诱导表达PTEN的Treg,而PTEN缺陷小鼠无法维持对凋亡细胞的耐受性。在患有大型已形成肿瘤的野生型小鼠中,化疗或免疫治疗后对PTEN进行药理抑制可显著重塑肿瘤微环境,将其从抑制性环境转变为炎性环境,肿瘤迅速消退。因此,肿瘤中的免疫抑制环境必须被积极维持,如果Treg中的PTEN通路被破坏,肿瘤就会变得易受免疫攻击。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/4703236d0875/1500845-F6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/0db09f73e61e/1500845-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/c743a7d7a50e/1500845-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/7fb02739889d/1500845-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/3d4aee95bdd3/1500845-F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/6f861551e2fa/1500845-F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/4703236d0875/1500845-F6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/0db09f73e61e/1500845-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/c743a7d7a50e/1500845-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/7fb02739889d/1500845-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/3d4aee95bdd3/1500845-F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/6f861551e2fa/1500845-F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dee/4640592/4703236d0875/1500845-F6.jpg

相似文献

1
The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.调节性T细胞中的PTEN信号通路是抑制性肿瘤微环境的关键驱动因素。
Sci Adv. 2015 Nov 6;1(10):e1500845. doi: 10.1126/sciadv.1500845. eCollection 2015 Nov.
2
IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.吲哚胺2,3-双加氧酶、表达PTEN的调节性T细胞与小鼠肿瘤微环境中抗原呈递的调控
Cancer Immunol Immunother. 2017 Aug;66(8):1049-1058. doi: 10.1007/s00262-017-2010-2. Epub 2017 May 9.
3
Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.调节性 T 细胞(Treg)的失稳与重编程:对癌症免疫治疗的启示。
Cancer Res. 2018 Sep 15;78(18):5191-5199. doi: 10.1158/0008-5472.CAN-18-1351. Epub 2018 Sep 4.
4
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.来自小鼠肿瘤引流淋巴结的浆细胞样树突状细胞通过吲哚胺2,3-双加氧酶直接激活成熟调节性T细胞。
J Clin Invest. 2007 Sep;117(9):2570-82. doi: 10.1172/JCI31911.
5
PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs.PTEN抑制白细胞介素-2受体介导的CD4+ CD25+调节性T细胞的扩增。
J Clin Invest. 2006 Sep;116(9):2521-31. doi: 10.1172/JCI28057. Epub 2006 Aug 17.
6
Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?PTEN缺陷型肿瘤与免疫抑制性肿瘤微环境之间是否存在因果联系?
J Transl Med. 2020 Jan 30;18(1):45. doi: 10.1186/s12967-020-02219-w.
7
Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by Hras and Pten Loss.肿瘤微环境中髓系和淋巴系来源的免疫细胞介导的免疫抑制促进了由Hras和Pten缺失驱动的甲状腺癌进展。
J Clin Cell Immunol. 2016 Oct;7(5). doi: 10.4172/2155-9899.1000451. Epub 2016 Sep 16.
8
Intratumoral regulatory T cells with higher prevalence and more suppressive activity in hepatocellular carcinoma patients.肝癌患者肿瘤内调节性 T 细胞的患病率更高,抑制活性更强。
J Gastroenterol Hepatol. 2013 Sep;28(9):1555-64. doi: 10.1111/jgh.12202.
9
Cellular immune responses towards regulatory cells.针对调节性细胞的细胞免疫反应。
Dan Med J. 2016 Jan;63(1):B5188.
10
Kinetics and activation requirements of contact-dependent immune suppression by human regulatory T cells.人调节性 T 细胞接触依赖性免疫抑制的动力学和激活要求。
J Immunol. 2012 Jun 1;188(11):5459-66. doi: 10.4049/jimmunol.1101367. Epub 2012 Apr 25.

引用本文的文献

1
Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy.免疫细胞重编程中的代谢检查点:为癌症治疗重新调整免疫代谢
Mol Cancer. 2025 Aug 2;24(1):210. doi: 10.1186/s12943-025-02407-6.
2
Regulatory T cells in the tumour microenvironment.肿瘤微环境中的调节性T细胞。
Nat Rev Cancer. 2025 Jun 10. doi: 10.1038/s41568-025-00832-9.
3
Immunometabolism of regulatory T cells in cancer.癌症中调节性T细胞的免疫代谢

本文引用的文献

1
Neoantigens in cancer immunotherapy.肿瘤免疫治疗中的新生抗原
Science. 2015 Apr 3;348(6230):69-74. doi: 10.1126/science.aaa4971.
2
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.肿瘤特异性细胞毒性T淋巴细胞活性决定结直肠癌患者的预后。
J Clin Invest. 2015 Feb;125(2):739-51. doi: 10.1172/JCI74894. Epub 2014 Dec 22.
3
Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses.调节性T细胞需要磷酸酶PTEN来抑制辅助性T细胞1型(TH1)和滤泡辅助性T细胞(TFH)的反应。
Oncogene. 2025 Jul;44(25):2011-2024. doi: 10.1038/s41388-025-03458-1. Epub 2025 Jun 4.
4
Vps34-orchestrated lipid signaling processes regulate the transitional heterogeneity and functional adaptation of effector regulatory T cells.Vps34 介导的脂质信号传导过程调节效应调节性 T 细胞的过渡异质性和功能适应性。
PLoS Biol. 2025 Apr 11;23(4):e3003074. doi: 10.1371/journal.pbio.3003074. eCollection 2025 Apr.
5
Tumor suppressor genes in the tumor microenvironment.肿瘤微环境中的肿瘤抑制基因。
Dis Model Mech. 2025 Mar 1;18(3). doi: 10.1242/dmm.052049. Epub 2025 Mar 20.
6
Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33.淋巴结巨噬细胞通过诱导免疫调节细胞因子白细胞介素-33来驱动免疫耐受和对癌症治疗的抗性。
Cancer Cell. 2025 May 12;43(5):955-969.e10. doi: 10.1016/j.ccell.2025.02.017. Epub 2025 Mar 6.
7
Anti-PD-1 amplifies costimulation in melanoma-infiltrating T1-like Foxp3 regulatory T cells to alleviate local immunosuppression.抗程序性死亡蛋白1(Anti-PD-1)增强黑色素瘤浸润的T1样叉头框蛋白3(Foxp3)调节性T细胞中的共刺激,以减轻局部免疫抑制。
J Immunother Cancer. 2025 Jan 6;13(1):e009435. doi: 10.1136/jitc-2024-009435.
8
Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy.肿瘤免疫微环境中浸润性调节性T细胞重编程及其免疫治疗优化
Biomark Res. 2024 Sep 4;12(1):97. doi: 10.1186/s40364-024-00630-9.
9
Research progress on the role of PTEN deletion or mutation in the immune microenvironment of glioblastoma.PTEN缺失或突变在胶质母细胞瘤免疫微环境中的作用研究进展
Front Oncol. 2024 Aug 14;14:1409519. doi: 10.3389/fonc.2024.1409519. eCollection 2024.
10
Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression.调节性 T 细胞(Tregs)在肿瘤微环境中的复杂作用:其分子机制及其对癌症进展的双向影响。
Int J Mol Sci. 2024 Jul 4;25(13):7346. doi: 10.3390/ijms25137346.
Nat Immunol. 2015 Feb;16(2):178-87. doi: 10.1038/ni.3076. Epub 2015 Jan 5.
4
Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability.调节性T细胞中PI(3)激酶的调控维持内环境稳定和谱系稳定性。
Nat Immunol. 2015 Feb;16(2):188-96. doi: 10.1038/ni.3077. Epub 2015 Jan 5.
5
CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance.在抗肿瘤免疫监视中产生白细胞介素-12 的 CD103+树突状细胞。
Cancer Cell. 2014 Nov 10;26(5):591-3. doi: 10.1016/j.ccell.2014.10.008.
6
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.检查点阻断癌症免疫疗法靶向肿瘤特异性突变抗原。
Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.
7
PD-1 blockade induces responses by inhibiting adaptive immune resistance.程序性死亡受体1(PD-1)阻断通过抑制适应性免疫抵抗来诱导反应。
Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.
8
Genetic basis for clinical response to CTLA-4 blockade in melanoma.黑色素瘤中CTLA-4阻断临床反应的遗传基础。
N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi: 10.1056/NEJMoa1406498. Epub 2014 Nov 19.
9
Continuous requirement for the TCR in regulatory T cell function.调节性 T 细胞功能中持续的 TCR 需求。
Nat Immunol. 2014 Nov;15(11):1070-8. doi: 10.1038/ni.3004. Epub 2014 Sep 28.
10
Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.突变新抗原表位的基因组和生物信息学分析揭示了预测抗癌免疫原性的新规则。
J Exp Med. 2014 Oct 20;211(11):2231-48. doi: 10.1084/jem.20141308. Epub 2014 Sep 22.